Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
You may also be interested in...
Hengrui’s second major in-licensing deal this year is the latest example of the Chinese pharma innovation darling’s eagerness for new assets, particularly as some of its other products come under pressure.
Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.
Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.